Uncategorized

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

Published

on

AstraZeneca is pushing its small molecule GLP-1 drug to Phase 3 development for weight control, diabetes and other cardiometabolic conditions despite the asset failing to best one from Structure Therapeutics.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version